Durvalumab and Tremelimumab before surgery in patients with HR+/HER2-negative breast cancer
by Impact Journals LLCAnalysis of immune cell subsets during neoadjuvant therapy. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28567A new research paper was published inOncotarg
Updated on: March 30,2024
12
Durvalumab and Tremelimumab before surgery in patients with HR+/HER2-negative breast cancer
by Impact Journals LLCAnalysis of immune cell subsets during neoadjuvant therapy. Credit:Oncotarget(2024). DOI: 10.18632/oncotarget.28567A new research paper was published inOncotarg
Updated on:March 30,2024
12